Esperion Phase IIa ETC-588 ACS data

ESPR said its Phase IIa study of ETC-588 large unilamellar vesicules (LUV) to treat acute coronary syndromes (ACS) met the primary endpoints of safety and tolerability in 34 patients with stable atherosclerosis. The company said patients showed dose-related cholesterol mobilization, and that optimal dosing of the compound is every 7 days. ...